Novel Models of Biotech IP Licensing: How Early Can it Start?
Home > Presentation > Novel Models of Biotech IP Licensing: How Early Can it Start?
Dramatic events in the Intellectual Property (IP) world of the past 18 months have created a new landscape. These included passage of the America Invents Act (new patent law), Nortel patent auction sale for $4.5 billion, Google acquisition of Motorola for its patents for $12.5 billion, and a series of fundamental federal and Supreme Court decisions. Coupled with changes in life science VC funding, “new rules” at the FDA, reimbursement challenges, and Large Co. R&D gap, this opens up thrilling opportunities for IP-savvy biotech leaders of all sizes. Novel IP licensing modalities will be explored, with case studies from lifescience and other industries, finishing with a “how to” session.